{"id":"ebv-specific-t-cells-a","_chembl":null,"modality":"Biologic","_dailymed":null,"mechanism":{"target":"EBV antigens","explanation":"The therapy involves isolating and expanding T cells that recognize EBV-associated antigens. When infused into patients, these cells seek out and destroy EBV-infected or EBV-transformed cells through cytotoxic immune responses, providing targeted immunotherapy for EBV-related diseases.","oneSentence":"Adoptive transfer of T cells specifically engineered or selected to recognize and eliminate cells infected with or transformed by Epstein-Barr virus."},"_scrapedAt":"2026-03-28T04:36:45.847Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123470,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"Tabelecleucel","brand":"EBVALLO","company":"Atara Biotherapeutics","rationale":"Allogeneic EBV-specific T-cell therapy for EBV-driven diseases"},{"name":"Rituximab","brand":"Rituxan","company":"Genentech/Roche","rationale":"Standard treatment for EBV-associated B-cell lymphoproliferative disorders"}],"description":"EBV-specific T cells: A is an investigational cell therapy developed by Baylor College of Medicine. It consists of T lymphocytes specifically targeted against Epstein-Barr virus (EBV) antigens, designed to treat EBV-associated malignancies and complications in immunocompromised patients.","indications":{"approved":[{"status":"investigational","condition":"EBV-associated post-transplant lymphoproliferative disease","patientPopulation":"Transplant recipients"},{"status":"investigational","condition":"EBV-positive lymphomas","patientPopulation":"Immunocompromised patients"}]},"trialDetails":[{"nctId":"NCT02287311","phase":"PHASE1","title":"Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2015-02","conditions":"Hodgkin Disease, Non-Hodgkin Lymphoma, Severe Chronic Active Epstein Barr Virus","enrollment":38},{"nctId":"NCT06391814","phase":"NA","title":"Donor-Derived EBV-Specific T Cells for Life Threatening EBV-lymphoma (OLIP-EBV-TCL-01-HMR01)","status":"COMPLETED","sponsor":"Ciusss de L'Est de l'Île de Montréal","startDate":"2024-01-16","conditions":"EBV Associated Lymphoma","enrollment":1},{"nctId":"NCT03180216","phase":"PHASE1","title":"T-Lymphocytes for Prevention or Treatment of Viral Infections Following Hematopoietic Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's National Research Institute","startDate":"2017-02-15","conditions":"Viral Infections, Bone Marrow Transplant Infection","enrollment":32},{"nctId":"NCT07476014","phase":"EARLY_PHASE1","title":"Early Clinical Study on the Use of Donor-derived EBV-specific T Cells for the Prevention of EBV Infection After Allogeneic Hematopoietic Stem Cell Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-02-28","conditions":"Prevention of EBV Infection After Allogeneic Hematopoietic Stem Cell Transplantation","enrollment":18},{"nctId":"NCT07450391","phase":"PHASE1, PHASE2","title":"EBV-AST Cell Injection for EBV-Associated Lymphoproliferative Disorders","status":"RECRUITING","sponsor":"Daihong Liu","startDate":"2025-06-01","conditions":"Epstein-Barr Virus-Associated Lymphoproliferative Disorders, EBV-Positive Lymphoma","enrollment":18},{"nctId":"NCT01555892","phase":"PHASE1","title":"Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2013-01-14","conditions":"Hodgkin's Disease, Non-Hodgkin's Lymphoma, Lymphoproliferative Disease","enrollment":136},{"nctId":"NCT03394365","phase":"PHASE3","title":"A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy","status":"RECRUITING","sponsor":"Pierre Fabre Medicament","startDate":"2017-12-29","conditions":"Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders","enrollment":115},{"nctId":"NCT04554914","phase":"PHASE2","title":"A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases","status":"RECRUITING","sponsor":"Pierre Fabre Medicament","startDate":"2021-07-14","conditions":"Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD)","enrollment":190},{"nctId":"NCT06761677","phase":"PHASE1, PHASE2","title":"A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma","status":"SUSPENDED","sponsor":"SymBio Pharmaceuticals","startDate":"2025-06-09","conditions":"Relapsed or Refractory Lymphoma Including ENKL","enrollment":43},{"nctId":"NCT00709033","phase":"PHASE1","title":"T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2009-07","conditions":"Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia","enrollment":3},{"nctId":"NCT02900976","phase":"PHASE2","title":"Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2017-03-22","conditions":"EBV-Related Post-Transplant Lymphoproliferative Disorder, Monomorphic Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder","enrollment":18},{"nctId":"NCT04664179","phase":"PHASE1","title":"EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2022-10-31","conditions":"EBV-Related Hodgkin Lymphoma, EBV-Related Lymphoproliferative Disorder, EBV Related Non-Hodgkin's Lymphoma","enrollment":52},{"nctId":"NCT00368082","phase":"PHASE1","title":"Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2006-04","conditions":"Lymphoma, Hodgkin's Disease, Relapse","enrollment":8},{"nctId":"NCT06909110","phase":"PHASE1, PHASE2","title":"Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity","status":"RECRUITING","sponsor":"Jessie L. Alexander","startDate":"2025-04-30","conditions":"Adenovirus, Cytomegalovirus Infections, Epstein-Barr Virus Infections","enrollment":25},{"nctId":"NCT04013802","phase":"PHASE1","title":"TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2021-03-08","conditions":"Viral Infection","enrollment":47},{"nctId":"NCT03266653","phase":"PHASE2","title":"EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection","status":"RECRUITING","sponsor":"New York Medical College","startDate":"2020-07-07","conditions":"Epstein-Barr Virus Infections, Primary Immune Deficiency Disorder","enrollment":20},{"nctId":"NCT06926894","phase":"PHASE1","title":"R-MVST Cells for Treatment of Viral Infections in Children and Young Adults","status":"RECRUITING","sponsor":"Columbia University","startDate":"2025-04-20","conditions":"Epstein-Barr Virus, Cytomegalovirus Infections, Adenovirus","enrollment":18},{"nctId":"NCT04288726","phase":"PHASE1","title":"Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2020-09-16","conditions":"Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Classical Hodgkin Lymphoma","enrollment":18},{"nctId":"NCT04832607","phase":"PHASE3","title":"Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV Infections","status":"RECRUITING","sponsor":"Tobias Feuchtinger","startDate":"2019-08-27","conditions":"AdV Infection, EBV Infection, CMV Infection","enrollment":149},{"nctId":"NCT02510417","phase":"PHASE1","title":"Allogeneic Virus-specific T Cell Lines (VSTs)","status":"COMPLETED","sponsor":"Catherine Bollard","startDate":"2014-10-28","conditions":"Viral Infections After HSCT","enrollment":31},{"nctId":"NCT01430390","phase":"PHASE1","title":"In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2011-09","conditions":"Acute Lymphocytic Leukemia, Lymphoma","enrollment":19},{"nctId":"NCT02580539","phase":"PHASE1, PHASE2","title":"A Study of the Safety and Efficacy of EBV Specific T-cell Lines","status":"COMPLETED","sponsor":"Dr. Jean-Sebastien Delisle, MD, PhD","startDate":"2015-11","conditions":"Epstein-Barr Virus Infections, Post-Transplant Lymphoproliferative Disorder, Lymphoma","enrollment":12},{"nctId":"NCT03475212","phase":"PHASE1, PHASE2","title":"Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pediatric Transplantation & Cellular Therapy Consortium","startDate":"2018-06-20","conditions":"Cytomegalovirus Infections, Adenovirus Infection, EBV Infection","enrollment":52},{"nctId":"NCT02007356","phase":"PHASE2","title":"A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System®","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2014-12","conditions":"Adenovirus Infection, EBV, Cytomegalovirus Infections","enrollment":30},{"nctId":"NCT05688241","phase":"PHASE1, PHASE2","title":"EBV-Tscm Cytotoxic T Cells (CTLs) for EBV- Driven Lymphomas/ Diseases","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2026-11","conditions":"EBV Lymphoma, Post-transplant Lymphoproliferative Disease (PTLD)","enrollment":10},{"nctId":"NCT02912897","phase":"PHASE1","title":"Trial to Assess the Safety and Feasibility of Adoptive Cell Therapy with Autologous EBV-specific Cytotoxic T Lymphocytes (CTL) in Patients with a First Clinical Episode Highly Suggestive of Multiple Sclerosis","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2021-01-26","conditions":"Multiple Sclerosis","enrollment":7},{"nctId":"NCT05471661","phase":"PHASE1, PHASE2","title":"T Lymphocytes for the Treatment of AdV, CMV, EBV, BKV and Aspergillus Fumigatus Infections After Allogeneic Stem Cell Transplantation","status":"COMPLETED","sponsor":"George Papanicolaou Hospital","startDate":"2021-05-22","conditions":"Opportunistic Fungal Infection, Opportunistic Viral Infection, Bone Marrow Transplant Infection","enrollment":10},{"nctId":"NCT01956084","phase":"PHASE1","title":"Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma","status":"COMPLETED","sponsor":"Catherine Bollard","startDate":"2013-11","conditions":"Hodgkin Disease, Non Hodgkin Lymphoma, Lymphoepithelioma","enrollment":10},{"nctId":"NCT03769467","phase":"PHASE1, PHASE2","title":"Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)","status":"TERMINATED","sponsor":"Atara Biotherapeutics","startDate":"2019-02-19","conditions":"Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections","enrollment":12},{"nctId":"NCT03594981","phase":"PHASE1, PHASE2","title":"Adoptive Cord Blood Immunotherapy for EBV, CMV, BKV and Adenovirus Reactivation/Infection or Prophylaxis","status":"RECRUITING","sponsor":"Catherine Bollard","startDate":"2018-01-24","conditions":"Viral Infection","enrollment":36},{"nctId":"NCT03131934","phase":"EARLY_PHASE1","title":"Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"University College, London","startDate":"2019-05-31","conditions":"Post-transplant Lymphoproliferative Disease, Transplant-Related Hematologic Malignancy","enrollment":18},{"nctId":"NCT05075837","phase":"PHASE1","title":"Adoptive T-cell Therapy for Resistant Viral Infections After Allogeneic HSCT","status":"UNKNOWN","sponsor":"Istituto Giannina Gaslini","startDate":"2024-02-27","conditions":"Viral Infection After HSCT","enrollment":10},{"nctId":"NCT06075927","phase":"PHASE1, PHASE2","title":"Multivirus-specific T Cells in the Treatment of Refractory CMV and/or EBV Infection After Allo-HSCT","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2023-11-01","conditions":"CMV Infection, EBV Infection, Stem Cell Transplant","enrollment":29},{"nctId":"NCT04952584","phase":"PHASE1","title":"Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas","status":"WITHDRAWN","sponsor":"Baylor College of Medicine","startDate":"2024-03","conditions":"Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Classical Hodgkin Lymphoma","enrollment":""},{"nctId":"NCT02578641","phase":"PHASE3","title":"A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients","status":"COMPLETED","sponsor":"Tessa Therapeutics","startDate":"2014-07","conditions":"Nasopharyngeal Carcinoma","enrollment":330},{"nctId":"NCT00834093","phase":"PHASE2","title":"A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2009-04","conditions":"Nasopharyngeal Carcinoma","enrollment":18},{"nctId":"NCT05532826","phase":"NA","title":"Clinical Study of Donor EBV-CTL Infusion in Patients With CAEBV and EBV-HLH After Allo-HSCT","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2022-10-08","conditions":"Chronic Active Epstein-Barr Virus Infection, Virus-Associated Hemophagocytic Syndrome","enrollment":15},{"nctId":"NCT00002663","phase":"PHASE1, PHASE2","title":"Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies","status":"COMPLETED","sponsor":"Atara Biotherapeutics","startDate":"1995-03","conditions":"EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma","enrollment":58},{"nctId":"NCT01498484","phase":"PHASE2","title":"Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies","status":"COMPLETED","sponsor":"Atara Biotherapeutics","startDate":"2011-12","conditions":"EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma","enrollment":87},{"nctId":"NCT03789617","phase":"PHASE1, PHASE2","title":"A Multi-center, Single-arm, Open, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of EBViNT Cell (EBV Specific Autologous CD8+ T Cell) in Patients With Treatment Failed Epstein Barr Virus (EBV)-Positive Malignancies","status":"UNKNOWN","sponsor":"Eutilex","startDate":"2018-12-14","conditions":"EBV Associated Extranodal NK/T-cell Lymphoma, EBV-Associated GastricCarcinoma or Esophageal AdenoCarcinoma","enrollment":72},{"nctId":"NCT01535885","phase":"PHASE1","title":"Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against EBV, ADV, and CMV","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2012-02","conditions":"Epstein-Barr Virus Infections, Adenovirus, Cytomegalovirus Infections","enrollment":25},{"nctId":"NCT02973113","phase":"PHASE1","title":"Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2016-02-16","conditions":"NonHodgkin Lymphoma, Lymphoproliferative Disorders, EBV Related Lymphoma","enrollment":8},{"nctId":"NCT02108522","phase":"NA","title":"Multivirus-specific T Cells for the Treatment of Virus Infections After Stem Cell Transplant","status":"COMPLETED","sponsor":"AlloVir","startDate":"2014-06","conditions":"Infection","enrollment":82},{"nctId":"NCT02188719","phase":"PHASE1","title":"Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-12-17","conditions":"Liver Transplantation","enrollment":15},{"nctId":"NCT00598169","phase":"PHASE1","title":"Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"AIDS Malignancy Consortium","startDate":"2007-11","conditions":"Lymphoma","enrollment":23},{"nctId":"NCT01923766","phase":"PHASE1","title":"Cytotoxic T Cells to Prevent Virus Infections","status":"COMPLETED","sponsor":"Children's National Research Institute","startDate":"2013-09","conditions":"CMV, EBV, Adenovirus Infections","enrollment":10},{"nctId":"NCT03988582","phase":"PHASE2","title":"Safety and Effectiveness of EBV-specific Cytotoxic T Cells for the Treatment for EBV Lymphomas or Other EBV-associated Malignancies","status":"WITHDRAWN","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-06-11","conditions":"EBV Lymphomas, EBV-associated Malignancies","enrollment":""},{"nctId":"NCT00062868","phase":"PHASE1","title":"LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2003-09","conditions":"Hodgkin Disease, Non Hodgkin Lymphoma, Lymphoepithelioma","enrollment":74},{"nctId":"NCT01447056","phase":"PHASE1","title":"Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2012-02","conditions":"Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Lymphoproliferative Disorder","enrollment":37},{"nctId":"NCT00058591","phase":"PHASE1","title":"Treating Severe Chronic Epstein-Barr Virus (EBV) Infection With EBV Specific Cytotoxic T Lymphocytes (CTLs)","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2000-01","conditions":"Epstein-Barr Virus Infections","enrollment":13},{"nctId":"NCT02510404","phase":"PHASE1","title":"Multivirus-specific Cytotoxic T Lymphocytes (mCTL)","status":"COMPLETED","sponsor":"Catherine Bollard","startDate":"2014-04","conditions":"Refractory Viral Infections","enrollment":1},{"nctId":"NCT00058604","phase":"PHASE1","title":"Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs).","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2001-01","conditions":"Epstein-Barr Virus Infections, Lymphoproliferative Disorders","enrollment":12},{"nctId":"NCT03925896","phase":"PHASE1","title":"Phase I Trial of LMP2 Antigen-specific TCR T-cell Therapy for Recurrent and Metastatic NPC Patients","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-08-07","conditions":"Nasopharyngeal Carcinoma","enrollment":27},{"nctId":"NCT01570283","phase":"PHASE1, PHASE2","title":"ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus","status":"COMPLETED","sponsor":"AlloVir","startDate":"2012-09","conditions":"Viral Infection","enrollment":21},{"nctId":"NCT02763254","phase":"PHASE2","title":"Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas","status":"TERMINATED","sponsor":"Cell Medica Ltd","startDate":"2016-11","conditions":"Hodgkin Lymphoma, Lymphoma, Large B-Cell, Diffuse, Post-transplant Lymphoproliferative Disorder","enrollment":1},{"nctId":"NCT01948180","phase":"PHASE2","title":"Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma","status":"TERMINATED","sponsor":"Cell Medica Ltd","startDate":"2014-09","conditions":"Lymphoma, Extranodal NK-T-Cell, EBV","enrollment":15},{"nctId":"NCT01195480","phase":"PHASE1, PHASE2","title":"CD19-CAR Immunotherapy for Childhood Acute Lymphoblastic Leukemia (ALL)","status":"TERMINATED","sponsor":"University College, London","startDate":"2012-05","conditions":"Acute Lymphoblastic Leukemia","enrollment":29},{"nctId":"NCT01636388","phase":"PHASE2","title":"Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma","status":"TERMINATED","sponsor":"New York Medical College","startDate":"2013-01","conditions":"Hodgkins Lymphoma","enrollment":2},{"nctId":"NCT02057445","phase":"PHASE1","title":"3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma","status":"COMPLETED","sponsor":"New York Medical College","startDate":"2014-01","conditions":"Non-Hodgkins Lymphoma, Hodgkins Lymphoma, Lymphoproliferative Disorder","enrollment":1},{"nctId":"NCT00431210","phase":"PHASE1","title":"Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2007-02","conditions":"Nasopharyngeal Carcinoma","enrollment":28},{"nctId":"NCT00058617","phase":"PHASE1","title":"Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"1996-01","conditions":"Epstein-Barr Virus-Related Hodgkin Lymphoma, Epstein-Barr Virus-Related Non-Hodgkin Lymphoma, EBV Positive Plasma Cell Neoplasm","enrollment":13},{"nctId":"NCT01475058","phase":"PHASE1, PHASE2","title":"CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2012-04","conditions":"Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia","enrollment":1},{"nctId":"NCT00516087","phase":"PHASE1","title":"LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA)","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2007-08","conditions":"Nasopharyngeal Carcinoma","enrollment":23},{"nctId":"NCT00082225","phase":"PHASE1","title":"LMP2a-Specific Cytotoxic T-Lymphocytes, Lymphoma (ACDAL)","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"2003-10","conditions":"Lymphoma","enrollment":4},{"nctId":"NCT00711035","phase":"PHASE1, PHASE2","title":"Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL)","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2008-11","conditions":"Adenovirus Infection, EBV Infection","enrollment":50},{"nctId":"NCT00002956","phase":"PHASE1","title":"Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr Virus in Patients Who Have Undergone Organ Transplants","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"1996-11","conditions":"Leukemia, Lymphoma","enrollment":""},{"nctId":"NCT02456610","phase":"PHASE1","title":"Administration of Virus Specific CTLs for the Prophylaxis and Treatment of EBV/CMV Infections After HSCT in China","status":"UNKNOWN","sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","startDate":"2015-05","conditions":"Viral Infection","enrollment":30},{"nctId":"NCT01945619","phase":"","title":"Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CHALLAH)","status":"NO_LONGER_AVAILABLE","sponsor":"Baylor College of Medicine","startDate":"","conditions":"EBV Infection, CMV Infection, Adenoviral Infection","enrollment":""},{"nctId":"NCT00706316","phase":"PHASE1","title":"Administration of Epstein Barr Virus - Specific Cytotoxic T-Lymphocytes to Metastatic EBV-Positive Nasopharygneal Cancer","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2007-12","conditions":"Nasopharyngeal Cancer","enrollment":5},{"nctId":"NCT01070797","phase":"PHASE1","title":"Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE)","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2011-01","conditions":"Adenovirus Infection, Epstein-Barr Virus Infections, Cytomegalovirus Infections","enrollment":10},{"nctId":"NCT00006100","phase":"PHASE1","title":"Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes in Treating Patients With Progressive, Relapsed, or Refractory Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"Milton S. Hershey Medical Center","startDate":"2000-04","conditions":"Lymphoma","enrollment":""},{"nctId":"NCT00058773","phase":"PHASE1","title":"Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin Disease","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"1996-01","conditions":"Hodgkin Disease, Non-Hodgkins Lymphoma","enrollment":5},{"nctId":"NCT00005606","phase":"PHASE2","title":"Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2000-02","conditions":"Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm","enrollment":""},{"nctId":"NCT00779337","phase":"PHASE1","title":"Epstein-Barr Virus (EBV)-Specific T Cells as Therapy for Relapsed/Refractory EBV-positive Lymphomas","status":"COMPLETED","sponsor":"Queensland Institute of Medical Research","startDate":"2008-10","conditions":"Lymphoma","enrollment":8},{"nctId":"NCT00515957","phase":"PHASE1","title":"Study of LMP1- and LMP2- Specific Cytotoxic T-Lymphocytes (CTL)","status":"WITHDRAWN","sponsor":"Baylor College of Medicine","startDate":"2007-08","conditions":"NASOPHARYNGEAL CARCINOMA","enrollment":""},{"nctId":"NCT00690872","phase":"PHASE2","title":"Gemcitabine and Carboplatin Followed By Laboratory-Treated T Lymphocytes in Treating Patients With Metastatic or Locally Recurrent Epstein-Barr Virus-Positive Nasopharyngeal Cancer","status":"UNKNOWN","sponsor":"National Cancer Centre, Singapore","startDate":"2008-07","conditions":"Head and Neck Cancer","enrollment":35}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LMP, BARF1 and EBNA1 specific CTLs"],"phase":"phase_1","status":"active","brandName":"EBV-specific T cells: A","genericName":"EBV-specific T cells: A","companyName":"Baylor College of Medicine","companyId":"baylor-college-of-medicine","firstApprovalDate":"","aiSummary":"EBV-specific T cells are being studied as a treatment for various conditions, including EBV-related Hodgkin lymphoma, lymphoproliferative disorder, non-Hodgkin's lymphoma, chronic active Epstein-Barr virus infection, and virus-associated hemophagocytic syndrome. EBV-specific T cells are administered as a form of somatic cell supplemental therapy, where a specific dose of cells is given to the patient, with doses ranging from 2 x 10^7 cells/m2 to 6 x 10^7 cells/m2.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}